DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Urso 250 (Ursodiol) - Summary

 
 



URSO 250 SUMMARY

URSO 250™ is a bile acid available as 250 mg film-coated tablets for oral administration.

URSO 250™ (ursodiol) tablets are indicated for the treatment of patients with primary biliary cirrhosis.


See all Urso 250 indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Urso 250 (Ursodiol)

Primary Biliary Cirrhosis Treatment (PBC)
Source: MedicineNet ursodiol Specialty [2014.04.30]
Title: Primary Biliary Cirrhosis Treatment (PBC)
Category: Diseases and Conditions
Created: 8/21/2001 12:00:00 AM
Last Editorial Review: 4/30/2014 12:00:00 AM

Primary Biliary Cirrhosis (PBC)
Source: MedicineNet Liver Cancer Specialty [2014.04.23]
Title: Primary Biliary Cirrhosis (PBC)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/23/2014 2:58:18 PM

more news >>

Published Studies Related to Urso 250 (Ursodiol)

[Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial]. [Article in Korean] [2014]
ursodeoxycholic acid (UDCA) in patients with abnormal ALT... CONCLUSIONS: DDB was not inferior to UDCA for normalizing ALT level. Furthermore

Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. [2013]
No direct comparison of tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) has yet been carried out in the treatment of liver cirrhosis in China... However, both drugs exert no effect on the serum markers for liver fibrosis during 6-month treatment.

Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. [2012]
To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) with oral solubilized formula in amyotrophic lateral sclerosis (ALS) patients, patients with probable or definite ALS were randomized to receive oral solubilized UDCA (3.5 g/140 mL/day) or placebo for 3 months after a run-in period of 1 month and switched to receive the other treatment for 3 months after a wash-out period of 1 month...

Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. [2011.09]
BACKGROUND & AIMS: The combination of ursodeoxycholic acid (UDCA), colchicine, and methotrexate (MTX) is effective therapy for a subset of patients with primary biliary cirrhosis (PBC) who do not respond to UDCA. However, the durability of the response is unclear. We investigated whether the response to combination therapy was durable... CONCLUSIONS: Treatment with the combination of UDCA and MTX or UDCA and colchicine led to sustained clinical remission in a subset of patients with PBC. The response to the combination of UDCA and MTX appeared to be more durable than to UDCA and colchicine. Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. [2011.09]
OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28-30 mg/kg/day) UDCA on the development of colorectal neoplasia in patients with UC and PSC... CONCLUSIONS: Long-term use of high-dose UDCA is associated with an increased risk of colorectal neoplasia in patients with UC and PSC.

more studies >>

Reports of Suspected Urso 250 (Ursodiol) Side Effects

Sudden Cardiac Death (4)Confusional State (1)Jaundice (1)Productive Cough (1)Hepatic Function Abnormal (1)Hypoglycaemia (1)Rales (1)Pyrexia (1)Hypokalaemia (1)Liver Disorder (1)more >>


Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015